期刊文献+

NP和CAF方案治疗晚期乳腺癌疗效及副反应分析 被引量:2

Analysis of the effect and toxicity of NP and CAF regimen in the treatment for patients with advanced breast cancer
下载PDF
导出
摘要 目的比较NP和CAP方案对晚期乳腺癌的疗效和毒副反应。方法78例晚期乳腺癌患者分别接受NP、CAF方案的治疗,病例数分别为37和41,观察疗效和毒副反应。结果NP组总有效率为64.9%(其中初治组73.7%,复治组55.6%),CAF组有效率为41.5%(其中初治组52.4%,复治组30.0%)。两组初治、复治病例有效率差异无统计学意义(P>0.05),总有效率差异有统计学意义(P<0.05);其中位缓解期分别为7.6和8.1个月,中位生存期分别为17.5和18.6个月,两组差异无统计学意义。NP组静脉炎发生率多于CAF组,而CAF组心脏毒性及脱发多于NP组,其余不良反应发生率相近。结论NP方案是治疗晚期乳腺癌的有效方案,其不良反应均能耐受。 Objective To compare the effect and the toxicity of NP(navelbine+cisplatin)and CAF(cyclophosphamide+adriamycin+5-fluorouracil)regimen in the treatment for patients with advanced breast cancer.Methods Seventy-eight cases with advanced breast cancer were studied respectively 37 and 41 patients which were treated with NP and CAF regimen,respectively.Results In NP group the response of rates (RR)of initial treatment cases,the retreatment cases,and the whole cases were 73.7%,55.6% and 64.9%,respectively.whereas in CAF group,the RR of initial treatment cases,the retreatment cases and the whole cases were 52.4%,30.0%,and 41.5%,respectively.The median time to progression(TTP) and the median survival were 7.6 months and 17.5 months in NP group,respectively.The median TTP was 8.1 months and the median survival was 18.6 months in CAF group.There were sigmificant differences between two groups in the RR of the whole cases (P<0.05).However,there was no significant difference in the RR of the initial treatmemt cases and the retreatment cases,the median TTP and the median survival(P>0.05).Phlebitis was more serious in NP group than in CAF group(P<0.05);However,the toxicity of heart and alopecie was more serious in CAF group than in NP group(P<0.05).There was no significant difference in the other side effects between the two groups.Conclusion NP regimen is effective for the treatment of advanced breast cancer patients and all side effects were tolerable.
出处 《滨州医学院学报》 2005年第3期165-166,共2页 Journal of Binzhou Medical University
关键词 乳腺癌 化学疗法 长春瑞滨 阿霉素 breast cancer,chemotherapy,vinorelbine,adriamycin
  • 相关文献

参考文献5

二级参考文献6

  • 1潘启超.长春碱类的新进展──失碳长春碱[J].癌症,1996,15(3):228-231. 被引量:276
  • 2Monica Terenziani,Romano Demicheli,Cristina Brambilla,Laura Ferrari,Angela Moliterni,Milvia Zambetti,Augusto Caraceni,Cinzia Martini,Gianni Bonadonna.Vinorelbine: An active, non cross-resistant drug in advanced breast cancer. Results from a phase II study[J].Breast Cancer Research and Treatment.1996(3)
  • 3Terenziani M,Demicheli R,Brambilla C,et al.Vinorelbine: anactive non cross-resistant drug in advanced breast cancer.Results from a phase Ⅱ. study[].Breast Cancer Research.1996
  • 4Ray-Coquard I,Biron P,Bachelot T,et al.Vinorelbine and cisplatin(CIVIC regimen) for the treatment of metastatic breast carcinoma after failure of anthracycline-and (or) paclitaxel-contaning regimens[].Cancer.1998
  • 5Hohneker JA.A summary of vinorelbine (navelbine) safety data from north American clinical trials[].Seminars in Oncology.1994
  • 6郑勤,陈锦飞,张全安.含诺维本化疗方案治疗晚期乳腺癌近期疗效观察[J].浙江肿瘤,2000,6(1):22-23. 被引量:10

共引文献57

同被引文献6

引证文献2

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部